Our medical and scientific team continues research to improve therapies and offer additional treatment options. Contact a BioXcellerator Patient Advocate to see if new treatments are available for your condition.

Schedule Your Free Consultation

Free Consultation

Why Americans Travel Abroad for Stem Cell Therapy V2

How a public plea for research became a decades-long gap betweenscientific possibility and treatment access!

The Missing Stem Cell History

A 1998 myth your family still believes – and how it cost the US the leading role in stem cell therapy.

“It’s killing babies!” was the cry of political groups. Stem cell research literally pre-dates penicillin. Leading up to the 90s, as in vitro fertilization became a standard option for couples struggling to conceive, scientists learned they could extract stem cells from embryonic tissue. The embryos they supplied these cells were designated for medical waste – either because the couples were successful and did not need leftover embryos or because they were never successful.

One political group got wind of the cell source, shaped a narrative and ensnared the nation in a political fight about the science based on the source.

The day stem cells became a Congressional Debate

September 14, 2000, celebrities Mary Tyler Moore and Michael J. Fox went to Capitol Hill with a simple message: people living with serious disease could not afford for stem-cell research to remain trapped in political debate.

Mary Tyler Moore testifying at the 2000 congressional stem cell hearing

Moore, who had lived with type 1 diabetes since her thirties, spoke as chair of the Juvenile Diabetes Foundation. Fox had recently stepped away from his television career to focus on Parkinson’s disease. Christopher Reeve, paralyzed after a riding accident, submitted a written statement in support. They were not promoting a clinic or promising an immediate cure. They were asking the federal government to let scientists pursue a field that might one day produce new cells, tissues and treatment options for conditions medicine could manage but not reverse.

Fox warned that further delay could carry a high price.

Moore described stem-cell research as an enormous source of hope. Their testimony gave a complicated laboratory debate a human face: diabetes, Parkinson’s disease and spinal-cord injury were no longer abstractions. They belonged to people Americans knew.

What they were asking Congress to allow

The hearing centered primarily on human embryonic stem cells. In 1998, researchers had learned to maintain human embryonic stem-cell lines in the laboratory. Because these cells are pluripotent – capable of developing into many specialized cell types – scientists saw a new way to study disease and, potentially, replace damaged tissue.

The controversy concerned how those lines were derived (the cell source). Many came from early-stage embryos created through in-vitro fertilization that would otherwise be discarded. Supporters argued that donated material could advance research under strict ethical rules. Opponents believed destroying an embryo for research was morally unacceptable.

This distinction matters today. The 2000 debate was not about every type of stem cell. Adult stem cells, blood-forming stem cells, and cells obtained from donated umbilical-cord tissue after birth are biologically and ethically different. Yet the words stem cells became fused in the public mind with embryos, abortion and cloning. That association shaped American policy – and public understanding – for years.

Washington narrowed the lane rather than offering a highway

It is tempting to summarize what followed by saying “Congress banned stem-cell research”. That is not accurate. American scientists continued to study stem cells, private funding remained possible, and blood-forming stem-cell transplantation was already established for selected blood and immune disorders.

Merge road sign

But federal policy created a stop-start environment. Since 1996, the Dickey-Wicker Amendment has prevented federal funds from supporting research that creates or destroys human embryos. In 2000, the National Institutes of Health developed guidelines intended to permit federally funded researchers to work with human embryonic stem-cell lines derived using private funds. In 2001, President George W. Bush limited federal support to certain already-existing lines. Congress later passed legislation to expand access, but President Bush vetoed it in 2006 and again in 2007. President Barack Obama broadened the federal funding framework in 2009, while the underlying statutory restriction remained.

Research did not stop. But money, eligible cell lines, laboratory planning and political certainty all matter in a young field. The United States sent researchers and investors a mixed message: the science was important, but one of its most visible branches could become a political fault line with every election. The result was not a single prohibition. It was friction – years of legal uncertainty, funding limits and slower translation from discovery to patient care.

The Practical Effect

While Congress did not outright “ban” stem cell research in the US, it inadvertently pushed it offshore. Over the ensuing 25 years, we heard many stories about professional athletes flying to Israel, Lebanon, Brazil and South America for injections and treatments for rotator cuff tears, meniscus and knee injuries, shoulder issues and more. These treatments were made available to those who could afford to travel, and their experimental nature made them seem mysterious. They were not. They were stem cell infusions.

A new branch of science inherited the same caution

While America debated embryonic cells, another area was growing: mesenchymal stem or stromal cells, usually shortened to MSCs. Their scientific roots were in bone marrow, not embryos. Over time, researchers identified MSC-like populations in fat, dental tissue, placenta and umbilical-cord connective tissue known as Wharton’s jelly.

MSCs attracted interest because laboratory and early clinical studies suggested they might influence inflammation, immune activity and tissue repair. Scientists initially emphasized their ability to form tissues such as bone, cartilage and fat. Later research placed greater emphasis on the signals they release and how those signals may affect surrounding cells.

These developments avoided much of the embryo debate, but they did not automatically create a path to routine treatment in the United States. MSC products still had to fit a regulatory system designed to establish identity, consistency, safety and effectiveness before broad commercial use.

The FDA question in plain English

In the United States, the Food and Drug Administration does not prohibit all use of human cells. The dividing lines include how much the cells or tissue are processed and whether they are used for the same basic function they performed in the donor.

Some procedures using a patient’s own tissue may fall within narrower exceptions, depending on the facts. But when cells are isolated, expanded in culture, combined with other components or used for a different purpose, the resulting product may be regulated as a biologic drug. That generally means formal clinical studies and FDA review are required before it can be marketed for a particular condition.

This is why an American patient can read about MSC research for an orthopedic, neurologic or immune-mediated condition yet be unable to obtain the same type of expanded-cell protocol from a U.S. clinic. The research may exist; the product may still be investigational; and the regulatory authorization required for routine domestic marketing may not.

FDA oversight exists for a reason. Cell source, donor screening, sterility, manufacturing consistency, dose and delivery all matter. At the same time, developing a living-cell product is expensive and technically demanding. The American pathway tends to move condition by condition and product by product – not as a blanket approval of “stem-cell therapy.”

Athletes made the access gap visible

Elite athletes were among the first Americans to make medical travel for regenerative procedures part of the public conversation. Their careers are short, injuries are costly, and they have the resources to seek options beyond the standard playbook.

Bartolo Colon pitching for Oakland

In 2010, pitcher Bartolo Colón underwent a reported procedure in the Dominican Republic involving cells taken from his own fat and bone marrow and reinjected into his injured shoulder and elbow. His return to Major League Baseball drew enormous attention, although reporting at the time cautioned that no one could isolate how much of his recovery was attributable to the cell component rather than surgery, rehabilitation or natural healing.

In 2011, Peyton Manning was widely reported to have traveled to Europe for an experimental stem-cell procedure for his neck. That same year, Terrell Owens reportedly traveled to South Korea for a knee-related cell procedure. Hockey legend Gordie Howe later received an unapproved cell-based intervention in Mexico following severe strokes; his family reported improvement, while independent experts stressed that a personal outcome could not establish effectiveness.

Kobe Bryant’s repeated trips to Germany also became part of this narrative, but his best-known treatment was Regenokine or Orthokine – a blood-derived anti-inflammatory procedure, not a conventional stem-cell treatment. That distinction is important. “Regenerative medicine” is a broad category that can include platelet-rich plasma, blood-derived proteins, cell therapies and tissue-engineering approaches. They should not be treated as interchangeable.

These athletes did not prove that every overseas procedure worked. They proved something else: Americans with means, urgency and incomplete options were willing to cross borders for treatments unavailable or difficult to access at home.

Why the treatment ecosystem developed abroad

Countries including Colombia, Panama, Mexico, Germany, South Korea and the Dominican Republic developed their own regulatory frameworks, clinical expertise and medical-tourism infrastructure. Some allowed physicians to use particular cell preparations or regenerative protocols under pathways different from those in the United States.

World map with flight routes for medical travel

That does not mean every international clinic offers advanced care, or that “outside the FDA” means “without oversight.” Quality varies dramatically across countries and clinics. Some programs operate within national health regulations, maintain specialized laboratories, document cell identity and sterility, employ experienced physicians and follow patients over time. Others may provide little more than persuasive marketing.

For many Americans, travel is therefore not simply a search for looser rules. It is a search for a combination that may not be available domestically: expanded cells, different tissue sources, larger or repeated doses, multispecialty protocols, and a clinical team experienced in delivering them.

So why must some Americans go abroad

The short answer is not that America rejected all stem-cell science. It is that the country separated research promise from routine treatment access through two decades of political conflict, funding constraints and stringent product-by-product regulation.

Mary Tyler Moore and Michael J. Fox asked Congress to give science room to move. Science did move – but unevenly. American laboratories remained important, and the United States has achieved major cell and gene-therapy breakthroughs. Yet for many applications involving culture-expanded MSCs, what can be studied in America is still not the same as what can be commercially offered to a patient in America.

That gap helped create the modern medical traveler: a patient who has exhausted conventional options, understands that regenerative medicine is not a guaranteed cure, and is willing to evaluate care in another country.

The right question is not simply, “Is stem-cell therapy available overseas?” It is: Which cells are being used? Where do they come from? How are they processed and tested? What evidence supports their use for this condition? Who determines candidacy? What risks, alternatives and uncertainties are disclosed? And how will outcomes be measured after the patient returns home?

Twenty-six years after Moore and Fox appeared on Capitol Hill, their central argument still resonates. Patients need hope, but hope must be matched by evidence, transparency and responsible access. For some Americans, finding that combination still requires a passport.

Just Because It’s Local Does Not Mean It’s Trustworthy

At this point, six States have loosened regulations around Stem Cell therapies – but HOW those cells are derived/extracted, how they are quality-controlled and how they are administered is NOT regulated.

Sources

  1. CNN. Subcommittee hears testimony on stem cell research. September 14, 2000. https://www.cnn.com/2000/HEALTH/09/14/stemcell.hearing/index.html
  2. CBS News. Stars Back Stem Cell Research. September 13, 2000. https://www.cbsnews.com/news/stars-back-stem-cell-research/
  3. U.S. Government Accountability Office. Regenerative Medicine Therapeutic Applications Challenges and Policy Options. GAO-23-105430. 2023. https://www.gao.gov/products/gao-23-105430
  4. National Institutes of Health. NIH Guidelines for Human Stem Cell Research. https://stemcells.nih.gov/research-policy/guidelines-for-human-stem-cell-research
  5. NIH Office of Science Policy. Stem Cell and Developmental Biology Policy. https://osp.od.nih.gov/policies/stem-cell-and-developmental-biology-policy/
  6. U.S. Food and Drug Administration. Framework for the Regulation of Regenerative Medicine Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/framework-regulation-regenerative-medicine-products
  7. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
  8. ESPN. Chasing the miracle cure. October 2011. https://www.espn.com/espn/story/_/id/7058209/peyton-manning-last-star-linked-stem-cell-therapy-espn-magazine
  9. ESPN. MLB reviews treatment records on Yankees pitcher Bartolo Colon. July 2011. https://www.espn.com/new-york/mlb/story/_/id/6770216/mlb-reviews-treatment-records-new-york-yankees-bartolo-colon
  10. TIME. What to Know About Gordie Howe’s Controversial Stem Cell Treatment. June 2016. https://time.com/4364238/gordie-howe-stem-cell-treatment/
  11. Wired. Is Biologic Medicine for Real. April 2012. https://www.wired.com/2012/04/is-biologic-medicine-for-real/

Medical and regulatory note: This article is educational and does not provide medical advice. Cell-based interventions vary by product, indication, manufacturing method and jurisdiction. Availability outside the United States does not establish safety or effectiveness.

BioXcellerator, 4900 N. Scottsdale Rd, Suite 3700, Scottsdale, AZ 85251
BioXcellerator, Torre Medica 2, Office 944, Medellin, Colombia